RecruitingNot ApplicableNCT06453512

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema Using SCORAD, Patient Questionnaires and Skin Hydration Measurements


Sponsor

Dermal Laboratories Ltd

Enrollment

65 participants

Start Date

Oct 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema. The study will involve patients who are already using emollients as part of their treatment regime, switching to Doublebase Once. Patients will ideally apply the product once daily for 4 weeks and SCORAD assessments will be performed, and patient questionnaires will be completed. A subgroup of adult patients (up to 15 patients) will also undergo skin hydration measurements for the first 8 days to evaluate objective measurements of skin hydration in patients with atopic eczema. Photographs of the same, representative area of eczema will also be taken for all patients at baseline and after 4 weeks of using Doublebase Once.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Doublebase Once for people with atopic eczema. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDoublebase Once

Emollient


Locations(1)

Cripps Medical Centre

Nottingham, Nottinghamshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06453512


Related Trials